SGLT2 inhibitors show consistent cardio-renal protection in 70,000 patients

https://www.news-medical.net/news/20251107/SGLT2-inhibitors-show-consistent-cardio-renal-protection-in-70000-patients.aspx In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 participants across 10 major randomised controlled trials. The meta-analyses were conducted by the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists' Consortium (SMART-C), led by The George Institute for Global Health.